Inactivation of phosphoglycerate mutase and creatine kinase isoenzymes in human serum

N Durany, J Carreras, M Valentí, J Cámara, J Carreras

Aims/Background: Total phosphoglycerate mutase (PGM) activity in serum has been shown to be increased in acute myocardial infarction with the same time course as creatine kinase (CK) activity. However, the increase in the muscle (MM) and in the cardiac (MB) PGM isoenzymes was not as high as expected. The present study was undertaken to characterise PGM inactivation by serum and to compare it with serum CK inactivation.

Methods: The PGM and the CK activities of extracts of human heart, skeletal muscle, and brain were determined spectrophotometrically after incubation with different media, namely: plasma, whole serum, dialysed serum, heated serum, serum ultrafiltrate, urate solution, and buffer solution.

Results: Type MM PGM was inactivated by plasma, whole serum, heated serum, dialysed serum, and serum ultrafiltrate. Inactivation in dialysed serum was reduced by EDTA and largely reversed by thiol agents. Inactivation in serum ultrafiltrate was not prevented by EDTA and only partially reversed by dithiothreitol. The muscle and type BB CK isoenzymes were inactivated in all the tested media. The incubation of human and rabbit skeletal muscle PGM and CK in urate solution showed that urate does not affect mutase activity under conditions that inactivate CK.

Conclusions: These results confirm the mechanisms of CK inactivation proposed by others and show that the type M PGM subunit is inactivated by two different mechanisms, which appear to involve the thiol groups of the enzyme. One mechanism is caused by either a protein component or a protein bound serum component and involves calcium ions and/or another chelatable metal ion. The other mechanism is caused by a lower molecular weight serum component and is metal ion independent.

Materials and Methods

Materials

Enzymes, substrates, cofactors, and biochemicals were purchased from either Boehringer (Mannheim, Germany) or Sigma (St Louis, Missouri, USA). β-Mercaptoethanol was from Merck (Darmstadt, Germany) and bovine serum albumin was from Calbiochem (La Jolla, California, USA). Other chemicals were reagent grade. Cellulose acetate strips (TITAN III ISO-VIS 94 × 76 mm) were from Helena Laboratories (Beaumont, Texas, USA). Paper wicks (Whatman number 3) were from Whatman Ltd (Maidstone, UK).

Serum and Tissue Samples

Serum and plasma from healthy donors were provided by the Laboratory of Clinical Biochemistry of the Hospital Clinic i Provincial, Barcelona, Spain. Specimens from human heart and skeletal muscle were obtained during necropsy within 24 hours after death. Brain samples were provided by the Brain Bank of the Hospital Clinic i Provincial. Commercial rabbit muscle PGM and CK were obtained from Boehringer.

Tissue Extraction

Tissue extracts were prepared by homogenisation in 3 vol (wt/vol) of cold 20 mM Tris/HCl buffer, pH 7.5, containing 1 mM EDTA and 1 mM β-mercaptoethanol with a Polytron homogeniser (Lucern, Switzerland) (position 5, 20 seconds). Cellular debris was removed by centrifugation at 4°C for 60 minutes at 25,000 g, and the supernatants were used for the assay of enzyme activities and isoenzymes.

Abbreviations: CK, creatine kinase; DTT, dithiothreitol; PGM, phosphoglycerate mutase

ORIGINAL ARTICLE

Phosphoglycerate mutase (D-phosphoglycerate 2,3-phosphomutase; EC 5.4.2.1; PGM) is a glycolytic enzyme present in mammalian cells in large amounts that catalyses the interconversion of 3-phosphoglycerate and 2-phosphoglycerate in the presence of the cofactor 2,3-bisphosphoglycerate.1 In mammals there are three PGM isoenzymes, which are derived from the homodimeric and heterodimeric combinations of two different subunits (types M and B). These isoenzymes have a similar distribution and are found in most other tissues. All three isoenzymes (MM, BB, and MB) are present in substantial amounts in myocardial tissue only.2,4

We have shown that total serum PGM activity increases in acute myocardial infarction with the same time course as CK activity. However, the increase in MM PGM and MB PGM activities in the patients was not as high as expected. Therefore, the present study was undertaken to characterise PGM inactivation by serum and to ascertain whether or not urate is involved.

“We have shown that total serum phosphoglycerate mutase activity increases in acute myocardial infarction with the same time course as creatine kinase activity”
Enzyme and protein assay
PGM activity was measured spectrophotometrically at 30°C, by coupling the formation of 2-phosphoglycerate from 3-phosphoglycerate with the enolase, pyruvate kinase, and lactate dehydrogenase catalysed reactions. The reaction mixture contained 100mM Tris/HCl, 0.5mM EDTA, 100mM KCl, 10mM MgCl₂, 1.5mM ADP, 2mM 3-phosphoglycerate, 10μM 2,3-bisphosphoglycerate, 0.2mM NADH, enolase (0.3 U/ml), pyruvate kinase (0.15 U/ml), and lactate dehydrogenase (0.5 U/ml), pH 7.4.

CK activity was measured spectrophotometrically at 30°C, essentially as recommended by the International Federation of Clinical Chemistry, but without N-acetylcycteine in the assay mixture. The assay is based on the formation of ATP linked to the production of NADPH via hexokinase and glucose-6-phosphate dehydrogenase. The reaction mixture contained 100mM imidazole acetate, 2mM EDTA, 10mM magnesium acetate, 2mM ADP, 2mM NADP, 30mM phosphocreatine, hexokinase (3 U/ml), and glucose-6-phosphate dehydrogenase (2 U/ml), pH 6.7. Protein was determined by the method of Bradford, using bovine serum albumin as a standard.

Isoenzyme analysis
Electrophoretic evaluation of PGM isozymes was performed as described previously. Cellulose acetate strips were presoaked in sodium barbitral buffer (50mM, pH 8.6) and contact with the electrophoresis buffer was made using Whatman number 3 paper wicks. The samples (0.5 μl) were applied by means of a commercial applicator kit and electrophoresis was performed for 60 minutes at 4°C and 250 V.

The bands with PGM activity were stained using a mixture containing 10mM Tris/HCl, 10mM MgSO₄, 20mM KCl, 10mM MnCl₂, 1.5mM ADP, 2mM 3-phosphoglycerate, 10μM 2,3-bisphosphoglycerate, 0.2mM NADH, enolase (0.3 U/ml), pyruvate kinase (0.15 U/ml), and lactate dehydrogenase (0.5 U/ml), pH 7.4.

RESULTS
Effects of serum components on the stability of PGM and CK isoenzymes
To detect the effects of human plasma and serum on the stability of the MM, MB, and BB PGM isoenzymes, extracts of human heart were incubated in whole plasma and serum, and with heated serum at 37°C and at 0°C. In all cases, incubation at 37°C produced a progressive decrease of the total PGM activity and a progressive inactivation of the MM PGM isoenzyme (fig 1; table 1). In contrast, incubation at 0°C had no effect. The addition of dithiothreitol (DTT) at the end of the various incubation periods at 37°C partially restored the lost total and MM PGM enzymatic activity (data not shown).

To compare the effects of the components of human serum on the stability of the PGM and CK isoenzymes extracts of human skeletal muscle and brain were incubated at 37°C in Tris buffer solution (pH 7.5), in whole serum, in dialysed serum, in heated serum, and in serum ultrafiltrate. Incubations were performed in the absence and in the presence of EDTA to differentiate the metal ion dependent and the metal ion independent effects. PGM and CK activities were measured at intervals, directly and after preincubation with DTT to detect any effects resulting from the oxidation of the SH groups of the enzymes.

PGM activity from skeletal muscle was remarkably stable at 37°C in Tris buffer pH 7.5: after 24 hours of incubation there was a loss of less that 10% of activity (fig 2). In contrast, PGM rapidly lost its activity when incubated in human serum: the activity was reduced by 60% after six hours, and only 20% of the original activity remained after 24 hours of incubation. The addition of EDTA to the serum during the incubation reduced the decrease in PGM activity: over a 24 hour period there was a 50% loss of activity. The addition of DTT at the end of the various incubation periods greatly restored the lost enzymatic activity. No loss of PGM activity was seen when muscle extract was incubated for 24 hours in whole serum at 0°C (data not shown).

The incubation of muscle extract in dialysed serum in the absence of EDTA continued to inactivate PGM activity, although at a rate lower than that seen for incubation with whole serum. PGM activity could be restored to a large extent by the addition of DTT after incubation. The addition of EDTA to the dialysed serum greatly decreased the rate of inactivation: less that 10% of activity was lost in 24 hours. Heating the whole and dialysed serum at 60°C for 30 minutes did not affect its capacity to inactivate PGM (data not shown).

Incubation of muscle extract in serum ultrafiltrate inactivated PGM at a rate similar to that seen for dialysed serum. However, the addition of EDTA to the ultrafiltrate during...
incubation did not affect the rate of inactivation, and the activity was only partially restored by the addition of DTT after incubation.

CK activity was fairly stable when muscle extract was incubated in Tris buffer, pH 7.5, at 37°C after a 24 hour period of incubation 80% of the activity remained (fig 3). When incubated in human serum, CK was inactivated at a rate higher than PGM; after three hours of incubation the activity was reduced by 77%. CK was also inactivated when incubated in dialysed serum and in serum ultrafiltrate, although in both cases the rate of CK inactivation was lower than that produced by incubation in whole serum. The addition of EDTA to the incubation medium did not prevent the loss of CK activity in any case. The addition of DTT after incubation slightly restored the CK activity lost by incubation in serum ultrafiltrate, and fully restored the enzymatic activity lost by incubation in whole and in dialysed serum.

Figure 4 illustrates the rate of decay of PGM activity in brain extract during incubation in the different media. As shown, when brain extract was incubated in Tris buffer solution, pH 7.5, the PGM activity was 50% lower after 24 hours of incubation. The addition of EDTA during incubation did not prevent the loss of PGM activity, and the addition of DTT after different periods of incubation did not restore the enzymatic activity. In contrast, when the brain extract was incubated in whole serum, the PGM activity was highly stable over a 24 hour period of incubation.

CK was inactivated when brain extract was incubated in Tris buffer, pH 7.5 (fig 5). The addition of EDTA to the incubation solution did not significantly modify the rate of CK inactivation and the addition of DTT after incubation only partially restored the loss of activity. When brain extract was incubated in whole human serum, CK was almost fully inactivated after a three hour period of incubation. The addition of EDTA to the serum did not prevent the inactivation of CK. Treatment with DTT after incubation partially restored the lost enzymatic activity. CK activity was also inactivated when the brain extract was incubated in dialysed serum and in serum ultrafiltrate. The addition of EDTA to the incubation medium did not prevent the inactivation of CK, and treatment with DTT after inactivation only partially restored the enzymatic activity (data not shown).

### Effect of urate on the stability of PGM and CK isoenzymes

It has been shown that urate inactivates human and rabbit skeletal muscle CK, and that DTT partially restores the activity of the urate inactivated enzymes. Therefore, we compared the effects of urate on the activity of CK and PGM in extracts of human skeletal muscle, and on the activity of purified PGM and CK from rabbit muscle. When the extract of human skeletal muscle was incubated at 25°C with urate in Tris buffer solution, pH 7.4, after 24 hours of incubation the CK activity was reduced by 55% and the PGM activity was not affected; that is, it suffered the same slight inactivation (about 20%) in the absence and in the presence of urate (table 2). Treatment with DTT after inactivation partially restored the lost CK activity. Similar results were obtained when purified rabbit muscle CK and PGM were incubated with urate. After 24 hours of incubation, the activity of rabbit muscle CK was reduced by 60%, whereas the activity of rabbit muscle PGM was only slightly affected. Treatment with DTT after inactivation partially restored CK activity.

### DISCUSSION

Our results confirm earlier findings that human serum inactivates PGM and show that the mechanism involved in PGM inactivation is complex and distinct from that implicated in CK inactivation.

Several studies have shown that CK is inactivated by human plasma and serum, and have shown that the three CK isoenzymes (MM, MB, and BB) are differently affected: MM CK is the most stable isoenzyme, MB CK is slightly less stable, and BB CK is the least stable isoenzyme. The rate of CK inactivation increased with temperature. Heating human serum at a temperature that should remove most enzymatic activity did not affect its capacity to inactivate CK isoenzymes. Ultrafiltration of plasma and serum through membrane filters that eliminate macromolecules did not prevent the inactivation of the MM and BB CK isoenzymes. Dialysis of serum produced contradictory results: human skeletal muscle CK was reported to be stable in dialysed serum, but rabbit muscle CK and human brain CK were found to be inactivated by dialysed serum. Albumin protected MM CK from inactivation when incubated in saline solution, but showed only a small protective effect when CK was incubated in whole serum, in dialysed serum, in

### Table 1: Stability of phosphoglycerate mutase (PGM) isoenzymes in human heart extract incubated in plasma and serum

<table>
<thead>
<tr>
<th>Incubation medium</th>
<th>Time</th>
<th>Total activity</th>
<th>% Activity of isoenzymes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>MM</td>
</tr>
<tr>
<td>Plasma at 0°C</td>
<td>0 minutes</td>
<td>100</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>12 hours</td>
<td>100</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>24 hours</td>
<td>100</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>48 hours</td>
<td>100</td>
<td>35</td>
</tr>
<tr>
<td>Plasma at 37°C</td>
<td>0 minutes</td>
<td>100</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>12 hours</td>
<td>57</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>24 hours</td>
<td>35</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>48 hours</td>
<td>23</td>
<td>0</td>
</tr>
<tr>
<td>Serum at 37°C</td>
<td>0 minutes</td>
<td>100</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>4 hours</td>
<td>47</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>24 hours</td>
<td>35</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>48 hours</td>
<td>22</td>
<td>12</td>
</tr>
<tr>
<td>Preheated serum</td>
<td>0 minutes</td>
<td>100</td>
<td>56</td>
</tr>
<tr>
<td>(60°C, 30 minutes)</td>
<td>4 hours</td>
<td>44</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>24 hours</td>
<td>35</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>48 hours</td>
<td>22</td>
<td>11</td>
</tr>
</tbody>
</table>

The activity of the isoenzymes is expressed as a percentage of the total activity on electrophoretogram.
heated serum, and in serum ultrafiltrate. Metal ion chelators did not prevent the inactivation of CK by whole serum or by heat inactivated serum. Thiol reagents produced only partial protection against inactivation of CK isoenzymes by plasma, by plasma ultrafiltrate, by whole serum, and partially reactivated the CK isoenzymes inactivated by incubation in whole plasma, plasma ultrafiltrate, whole serum, heated serum, and serum ultrafiltrate.

From all these data, which have been confirmed by our results, it was suggested that CK isoenzymes undergo two distinct types of inactivation when incubated in human plasma.
or serum: a rapid inactivation, presumably oxidative in nature, that is reversible with thiol agents, and a gradual inactivation, presumably thermal in nature, that is not reversible and is temperature dependent. The reversible CK inactivation seems to be mediated through a substance(s) in serum that is both protein bound and free. Two endogenous CK inhibitors have been isolated from human serum: urate and cystine. All three CK isoenzymes have been found to be inactivated by uric acid solutions. Serum proteins decreased the inactivation of CK produced by uric acid, and the inactivation
was reversed by dilution. The SH groups of CK appeared to be involved in the inactivation produced by urate: it was shown that the thiol reagents prevent and reverse this inactivation, and that there is a reduction in the number of reactive SH groups from eight for each dimer to four in the inactivation of rabbit muscle CK. Paradoxically, urate retarded the irreversible thermal inactivation of CK isoenzymes and preserved their integrity. 

The mechanism of CK inhibition by cystine appeared to be non-competitive with respect to adenine nucleotide and guanidine substrates, and it has been postulated to involve a disulfide interchange reaction, reversible by reducing agents.

"Our results show that there are several differences between the inactivation of PGM isoenzymes and the inactivation of CK isoenzymes by serum, namely:

1. Type MM PGM, which is highly stable when incubated in saline solution is progressively inactivated when it is incubated in human whole serum. In contrast, the activity of type BB PGM is not affected when the enzyme is incubated in serum under similar conditions. Thus, human serum contains a PGM inactivation component(s), which is specific for the type M PGM subunit.

2. Type MM PGM is inactivated by dialysed serum, heated serum, and serum ultrafiltrate. This raises two possibilities: (a) the enzyme is inactivated by a serum component that is both protein bound and free, or (b) two types of PGM inactivators are present in serum, one of low molecular weight and one of high molecular weight.

3. The inactivation of MM PGM produced by the non-dialysable serum component(s) is greatly reduced by the presence of EDTA and is largely reversed by incubation with DTT. This suggests that this inactivation involves calcium ions and/or another chelatable metal ion, and implicates the SH groups of the enzyme.

4. The inactivation of MM PGM produced by the ultrafiltrable serum component(s) is not prevented by EDTA and is only partially reversed by DTT. This suggests that the mechanism of this inactivation is different to that of the inactivation produced by the non-ultrafiltrable serum component(s).

5. The incubation of MM PGM in urate solutions under conditions that inactivate MM CK does not affect the activity of PGM. Thus, urate is not the low molecular weight serum component that causes the inactivation of MM PGM.
From all these considerations it can be concluded that the inactivation of PGM by human serum is a complex process that involves serum components distinct from those implicated in the inactivation of CK. Human serum contains either a protein component or a protein bound component that inactivates MM PGM through a mechanism that seems to involve calcium and/or another chelatable metal ion, and probably the SH groups of the enzyme. This component does not affect MM CK, which is inactivated by a non-dialysable serum component, the mechanism of action of which does not involve chelatable metal ions. In addition, similar to MM CK, MM PGM is inactivated by a low molecular weight serum component with a metal ion independent mechanism of action, which could involve the SH groups of the enzyme. However, urate, which is one of the serum components that inactivates MM CK, does not affect MM PGM.

Table 2  Inactivation of creatine kinase (CK) and phosphoglycerate mutase (PGM) activity by urate

<table>
<thead>
<tr>
<th></th>
<th>No urate</th>
<th>Plus urate</th>
<th>No urate</th>
<th>Plus urate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Human</td>
<td>Rabbit</td>
<td>Human</td>
<td>Rabbit</td>
</tr>
<tr>
<td>CK</td>
<td>100</td>
<td>88 (88)</td>
<td>77</td>
<td>38 (59)</td>
</tr>
<tr>
<td>PGM</td>
<td>45 (71)</td>
<td>80</td>
<td>77</td>
<td>82 (82)</td>
</tr>
</tbody>
</table>

Purified PGM and CK from rabbit muscle (3.8 mg/ml each) and human muscle extract (0.4 U/ml), previously reactivated by incubation with 10mM dithiothreitol (DTT) for 30 minutes at 30°C, were incubated at 25°C in buffer (50mM Tris/HCl, pH 7.4) in the presence and in the absence of 4mM urate. After 24 hours of incubation, the activities of PGM and CK were assayed directly and after a further 30 minutes of incubation at 30°C with 10mM DTT (numbers in parenthesis).

Figure 5  Inactivation of creatine kinase (CK) in human brain extracts incubated at 37°C in 20mM Tris HCl buffer pH 7.5 (A,B) and in whole serum (C,D). Extracts were incubated in the absence (A,C) and in the presence (B,D) of 5mM EDTA. The activity of PGM was measured directly (continuous lines) and after 30 minutes of incubation at 30°C with 10mM dithiothreitol (discontinuous lines).

Take home messages

- These results confirm earlier findings that human serum inactivates phosphoglycerate mutase (PGM)
- The mechanism of PGM inactivation is complex and distinct from that implicated in the inactivation of creatine kinase (CK)
- The type M PGM subunit is inactivated by two different mechanisms, which appear to involve the thiol groups of the enzyme
- One mechanism is caused by either a protein component or a protein bound serum component and involves calcium ions and/or another chelatable metal ion
- The other mechanism is caused by a lower molecular weight serum component and is metal ion independent

ACKNOWLEDGEMENTS

This work was supported by Generalitat de Catalunya, grant GRQ 94–1036.

Authors’ affiliations

N Durany, Health Science Faculty, International University of Catalunya, Gomera s/n, 08190 St. Cugat del Valles, Barcelona, Spain
J Carreras, M Valentí, J Cámara, J Carreras, Unit of Biochemistry and Molecular Biology, Faculty of Medicine, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Casanova, 143, 08036-Barcelona, Spain

REFERENCES

Phosphoglycerate mutase and creatine kinase isoenzymes


Inactivation of phosphoglycerate mutase and creatine kinase isoenzymes in human serum

N Durany, J Carreras, M Valentí, J Cámara and J Carreras

*Mol Path* 2002 55: 242-249
doi: 10.1136/mp.55.4.242

Updated information and services can be found at:
[http://mp.bmj.com/content/55/4/242](http://mp.bmj.com/content/55/4/242)

These include:

**References**
This article cites 29 articles, 10 of which you can access for free at:
[http://mp.bmj.com/content/55/4/242#BIBL](http://mp.bmj.com/content/55/4/242#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)